UCB Group Release: Neupro(R) Filed with the FDA for the Treatment of Advanced-Stage Parkinson's Disease
BRUSSELS, BELGIUM--(Marketwire - December 13, 2007) - The U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) for the use of Neupro® (Rotigotine Transdermal System) as adjunctive therapy with levodopa in adult patients with advanced-stage Parkinson's disease